Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma

Next Previous
Trial Profile

A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HDP 101 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Heidelberg Pharma AG

Most Recent Events

  • 24 Apr 2025 According to a Heidelberg Pharma AG media release,The analysis of the data is ongoing. The presentation of new clinical data is planned for the EHA Congress, a conference of the European Hematology Association, in Milan, Italy, in mid-June.
  • 24 Apr 2025 According to a Heidelberg Pharma AG media release,The first seven patient cohorts and dose levels have been completed.The Safety Review Committee (SRC) concluded that the 112.50 µg/kg dose is safe and well tolerated and study can continue with cohort 8((140 µg/kg)) .Patients in cohort 8 will also be dosed in two different arms.As long as patients in cohort 7 do not progress, they will continue to be treated with the previous dose level.
  • 13 Jan 2025 According to a Heidelberg Pharma AG media release, HDP-101 was well tolerated in Cohort 6, and the company looks forward to publishing first efficacy and additional safety data of this patient group at forthcoming scientific conferences in 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top